K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
Authors:
- 11 December 2006
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 38 (3-4) , 739-743
Abstract
Background: Mineral metabolism has emerged as an important predictor of morbidity and mortality in dialysis patients. Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in chronic kidney disease (CKD) recommend that, in Stage 5 CKD, the target levels for calcium (Ca) (corrected for serum albumin), phosphate (P), calcium × phosphate (Ca × P) product and parathyroid hormone (PTH) levels should be maintained at 8.4–9.5 mg/dl, 3.5–5.5 mg/dl, < 55 mg2/dl2 and 150–300 pg/ml, respectively. Objectives: To evaluate our ability to achieve K/DOQI guidelines for bone metabolism and disease targets in our patients and to compare them between patients on hemodialysis (HD) and peritoneal dialysis (PD) and also with those reported in the literature. Methods: We reviewed bone metabolism laboratory parameters in 57 HD patients and 69 PD patients, who had been on dialysis for more than 9 months. Results: The percentage of patients whose serum Ca, P, Ca × P product and PTH were within K/DOQI recommended target ranges were 46%, 53%, 77% and 28% in HD patients and 52%, 65%, 77% and 23% in PD patients, respectively. There were no significant differences between HD and PD patients in the percentage of all parameters that were within K/DOQI recommended target ranges. The percentage of our HD patients who had Ca, P, and PTH levels within recommended target range was similar to those in previous reports. Conclusion: In our unit, the management of bone and mineral metabolism in HD and PD patients is still far short of meeting K/DOQI guidelines. These findings appear similar in HD and PD patients. Our findings resemble those reported in the literature.Keywords
This publication has 32 references indexed in Scilit:
- Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonateKidney International, 2005
- Economic impact of sevelamer in patients with ESRDKidney International, 2005
- Opportunity and cost of sevelamer in dialysis patientsKidney International, 2005
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns StudyKidney International, 2005
- Efficacy and side‐effect profile of sevelamer hydrochloride used in combination with conventional phosphate bindersNephrology, 2004
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United StatesKidney International, 2004
- Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysisAmerican Journal of Kidney Diseases, 2004
- Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and cardiovascular calcificationClinical Nephrology, 2004
- Aluminum-Related Bone DiseaseBlood Purification, 1988